Abstract 27P
Background
There is growing evidence that elevated neutrophil to lymphocyte ratio (NLR) is associated with poor treatment response and survival outcomes in breast cancer. Also, standardized uptake value (SUV) of 18F-fluorodeoxyglucose (FDG) PET has been applied as a prognostic factor in breast cancer. In this study, we investigated the treatment response and survival outcomes according to NLR and SUV in breast cancer patients who received neoadjuvant chemotherapy (NAC).
Methods
Baseline NLR and SUVmax of 18F-FDG PET was retrospectively analyzed in 273 breast cancer patients who were received NAC followed by surgery from January 2007 to June 2018. Baseline NLR is calculated as absolute neutrophil count divided by absolute lymphocyte count from blood samples taken before initiation of NAC. Of the total, 101 patients underwent 18F-FDG PET after 3-4 cycles of NAC. The ΔSUVmax, the percentage reduction between SUVmax at baseline and after 3-4 cycles of NAC, was obtained from these patients. NLR and ΔSUVmax was classified as high and low relative to the median values (NLR: 2.04 and ΔSUVmax: 73.3%).
Results
The patients with pathologic complete response (pCR) had lower NLR and higher ΔSUVmax. Among all patients, high NLR was associated poor survival outcomes in terms of disease-free survival (DFS, adjusted HR 2.42; 95% Cis, 1.23-4.78; P = 0.011) and overall survival (OS, adjusted HR 1.53; 95% Cis, 1.19-1.97; P = 0.001), respectively. In 101 patients with data for early change of SUVmax, the high NLR (adjusted HR 3.20; 95% CIs, 1.29-7.89; P = 0.015) and low ΔSUVmax (adjusted HR 3.20; 95% CIs, 1.29-7.89; P = 0.015) were an independent prognostic factor for poor RFS. When patients were categorized into four groups according to NLR and ΔSUVmax, the patients with high NLR and low ΔSUVmax had significantly poor RFS (adjusted HR 8.71; 95% CIs, 1.87-40.64; P = 0.006) compared to those with low NLR and high ΔSUVmax.
Conclusions
Both the baseline NLR and ΔSUVmax were associated with treatment response and prognosis in breast cancer patients who received NAC. Moreover, we identified that metabolic non-responders with degraded immune system had a worst impact on survival outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
458P - Mutation tracking in circulating tumour DNA predicts relapse in completely resected EGFR-mutated NSCLC
Presenter: Martin Filipits
Session: Poster display session
Resources:
Abstract
460P - Mendelian randomization study showed no causality between metformin use and lung cancer risk
Presenter: Jiayi Shen
Session: Poster display session
Resources:
Abstract
461P - Blood trace minerals and lung cancer: A Mendelian randomization study
Presenter: Wei Xian
Session: Poster display session
Resources:
Abstract
463P - Prediction of invasiveness in lung adenocarcinoma using machine learning algorithm based on 3D-CT imaging
Presenter: Yusuke Saeki
Session: Poster display session
Resources:
Abstract
459P - Fish intake, dietary polyunsaturated fatty acids, and lung cancer: systematic review and dose-response meta-analysis of 1.7 million men and women
Presenter: Chao Cao
Session: Poster display session
Resources:
Abstract
462P - Usefulness for prevention of postoperative cerebrovascular complications in patients with lung cancer using carotid ultrasonography
Presenter: Sadanori Takeo
Session: Poster display session
Resources:
Abstract
468P - Histological type analysis of 10-year follow-up of WJTOG0105: A phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer
Presenter: Masahiro Tsuboi
Session: Poster display session
Resources:
Abstract
469P - Comparison of combined chemoradiotherapy regimens; Paclitaxel plus carboplatin and cisplatin plus etoposide for locally advanced non-small cell lung cancer: A randomised phase III trial
Presenter: Alper Ata
Session: Poster display session
Resources:
Abstract
472P - Integration of expression rate and absolute cell counts of PD-1+ stromal tumour-infiltrating lymphocytes: Prognostic significance in esophageal squamous cell carcinoma
Presenter: Qingkun Song
Session: Poster display session
Resources:
Abstract
467P - The free-circulating mtDNA copies number in plasma of patients with NSCLC
Presenter: Olga Bulgakova
Session: Poster display session
Resources:
Abstract